Multipolar Electrograms: A New Configuration That Increases the Measurement Accuracy of Intracardiac Signals.

BACKGROUND

Accurate measurements of intracardiac electrograms (EGMs) remain a clinical challenge because of the suboptimal attenuation of far-field potentials. Multielectrode mapping catheters provide an opportunity to construct multipolar instead of bipolar EGMs for rejecting common far-field potentials recorded from a multivectorial space.

OBJECTIVES

The purpose of this study was to develop a multipolar EGM and compare its characteristics to those of bipolar EGMs METHODS: Using a 36-electrode array catheter (Optrell-36; Biosense Webster), a far-field component was mathematically constructed from clusters of electrodes surrounding each inspected electrode. This component was subtracted from the unipolar waveform to produce a local unipolar, referred to as a "multipolar EGM." The performance of multipolar EGMs was evaluated in 7 swine with healed anteroseptal infarction.

RESULTS

Multipolar EGMs proved superior in attenuating far-field potentials in infarct border zones, increasing the near-field to far-field ratio from 0.92 ± 0.2 to 2.25 ± 0.3 (P < 0.001). Removal of far-field components reduced the voltage amplitude (P < 0.001) and enlarged the infarct surface area (P = 0.02), aligning more closely with histological findings. Of 379 EGMs with ≥20 ms activation time difference between bipolar and multipolar EGMs, 95.3% (361 of 379) were accurately annotated using multipolar EGMs, while annotation based on bipolar EGM was predominantly made on far-field components.

CONCLUSIONS

Multielectrode array catheters provide a unique platform for constructing multipolar EGMs. This new EGM may be beneficial for "purifying" local potentials within a complex electrical field, resulting in more accurate voltage and activation maps.

Informations de copyright

Copyright © 2024 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Funding Support and Author Disclosures This research was partially funded by Biosense Webster through a research grant. Dr Anter has received research grants and speaking honoraria from Biosense Webster, Boston Scientific, and Medtronic; and is a previous stockholder in Affera Inc Dr Barkagan has received consulting fees from Biosense Webster and Cardiodet. Dr Greenbaum, Mr Bubar, and Mr Yarnitsky are employees of Biosense Webster. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.